Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1 - PubMed (original) (raw)
Altered metabolic and adhesive properties and increased tumorigenesis associated with increased expression of transforming growth factor beta 1
B A Arrick et al. J Cell Biol. 1992 Aug.
Abstract
Transforming growth factor-beta (TGF-beta) is a potent mediator of cell proliferation and extracellular matrix formation, depending on the cell type and the physiological conditions. TGF-beta is usually secreted in a "latent" complex that needs activation before it can exert its effects. Several observations correlate increased expression of TGF-beta 1 with tumorigenesis. To evaluate the physiological relevance of increased TGF-beta 1 synthesis in tumor cells we established cell clones overexpressing TGF-beta 1 and observed the resulting physiological changes in TGF-beta overproducing cells in vitro and in vivo. As a model system we used the human E1A-transformed 293 tumor cells, which are insensitive to the direct growth modulatory effects of TGF-beta. The selection of this cell line allows an assessment of physiological alterations independent of TGF-beta induced proliferative changes. The use of two TGF-beta 1 expression vectors containing either the natural or a modified TGF-beta 1 precursor cDNA permitted the establishment of separate 293 cell lines overexpressing latent or active TGF-beta. Comparison of the resulting changes in glycolytic rate, adhesiveness and integrin and plasminogen activator expression established that, in vitro, both types of clones behaved similarly, indicating that expression of latent TGF-beta induces autocrine changes in the tumor cells and thus suggesting that some level of cell-associated activation occurs. TGF-beta overexpression resulted in an increased metabolic rate due to enhanced glycolysis, a property long associated with tumor cells. This increased glycolysis was not associated with altered proliferation. Cells overexpressing TGF-beta also displayed enhanced fibronectin mRNA and plasminogen activator synthesis and increased adhesiveness in vitro. They showed enhanced survival when plated sparsely on plastic in the absence of serum, and attached more readily to laminin. In addition, synthesis of several beta 1 integrins, in particular the alpha 1/beta 1, alpha 2/beta 1, and alpha 3/beta 1, all of which recognize laminin, were enhanced. Finally, cells overexpressing active TGF-beta, but not latent TGF-beta, also showed increased tumorigenicity in nude mice. Thus, an increase in endogenous TGF-beta synthesis confers several proliferation-independent phenotypic changes which may be of significance for the survival of the tumor cell inoculum or its subsequent growth, and for tumor formation and development. In the case of cells expressing active TGF-beta, the release of active TGF-beta into the vicinity of the tumor cells may also result in a more hospitable environment for tumor growth.
Similar articles
- Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA. Tobin SW, et al. Oncogene. 2002 Jan 3;21(1):108-18. doi: 10.1038/sj.onc.1205026. Oncogene. 2002. PMID: 11791181 - Extracellular matrix-associated transforming growth factor-beta: role in cancer cell growth and invasion.
Taipale J, Saharinen J, Keski-Oja J. Taipale J, et al. Adv Cancer Res. 1998;75:87-134. doi: 10.1016/s0065-230x(08)60740-x. Adv Cancer Res. 1998. PMID: 9709808 Review. - TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity.
Barrack ER. Barrack ER. Prostate. 1997 Apr 1;31(1):61-70. doi: 10.1002/(sici)1097-0045(19970401)31:1<61::aid-pros10>3.0.co;2-m. Prostate. 1997. PMID: 9108888 Review.
Cited by
- The role of phosphometabolites in cell proliferation, energy metabolism, and tumor therapy.
Mazurek S, Boschek CB, Eigenbrodt E. Mazurek S, et al. J Bioenerg Biomembr. 1997 Aug;29(4):315-30. doi: 10.1023/a:1022490512705. J Bioenerg Biomembr. 1997. PMID: 9387092 Review. - Transforming growth factor beta and the cell surface in tumor progression.
Newman MJ. Newman MJ. Cancer Metastasis Rev. 1993 Sep;12(3-4):239-54. doi: 10.1007/BF00665956. Cancer Metastasis Rev. 1993. PMID: 8281611 Review. - Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors.
Gonzalez-Junca A, Reiners O, Borrero-Garcia LD, Beckford-Vera D, Lazar AA, Chou W, Braunstein S, VanBrocklin H, Franc BL, Barcellos-Hoff MH. Gonzalez-Junca A, et al. Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):527-539. doi: 10.1016/j.ijrobp.2020.09.043. Epub 2020 Sep 29. Int J Radiat Oncol Biol Phys. 2021. PMID: 33007434 Free PMC article. - Latency and activation in the control of TGF-beta.
Barcellos-Hoff MH. Barcellos-Hoff MH. J Mammary Gland Biol Neoplasia. 1996 Oct;1(4):353-63. J Mammary Gland Biol Neoplasia. 1996. PMID: 10887509 Review. - TGF beta-induced growth inhibition in primary fibroblasts requires the retinoblastoma protein.
Herrera RE, Mäkelä TP, Weinberg RA. Herrera RE, et al. Mol Biol Cell. 1996 Sep;7(9):1335-42. doi: 10.1091/mbc.7.9.1335. Mol Biol Cell. 1996. PMID: 8885230 Free PMC article.
References
- Int J Cancer. 1991 Aug 19;49(1):129-39 - PubMed
- J Immunol. 1984 Jun;132(6):3011-8 - PubMed
- Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):580-4 - PubMed
- J Clin Invest. 1992 Jan;89(1):210-22 - PubMed
- J Immunol. 1992 Mar 1;148(5):1404-10 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials